Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 262

Similar articles for PubMed (Select 12432042)

1.
2.

C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women.

Ridker PM, Hennekens CH, Buring JE, Rifai N.

N Engl J Med. 2000 Mar 23;342(12):836-43.

3.

Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, MacFadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

N Engl J Med. 2008 Nov 20;359(21):2195-207. doi: 10.1056/NEJMoa0807646. Epub 2008 Nov 9.

4.

HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events.

Barter P, Gotto AM, LaRosa JC, Maroni J, Szarek M, Grundy SM, Kastelein JJ, Bittner V, Fruchart JC; Treating to New Targets Investigators.

N Engl J Med. 2007 Sep 27;357(13):1301-10.

5.

Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: justification for the use of statins in prevention: an intervention trial evaluating rosuvastatin (JUPITER).

Ridker PM, MacFadyen JG, Fonseca FA, Genest J, Gotto AM, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Study Group.

Circ Cardiovasc Qual Outcomes. 2009 Nov;2(6):616-23. doi: 10.1161/CIRCOUTCOMES.109.848473. Epub 2009 Sep 22.

6.

Polymorphisms associated with cholesterol and risk of cardiovascular events.

Kathiresan S, Melander O, Anevski D, Guiducci C, Burtt NP, Roos C, Hirschhorn JN, Berglund G, Hedblad B, Groop L, Altshuler DM, Newton-Cheh C, Orho-Melander M.

N Engl J Med. 2008 Mar 20;358(12):1240-9. doi: 10.1056/NEJMoa0706728.

8.
9.

The effect of including C-reactive protein in cardiovascular risk prediction models for women.

Cook NR, Buring JE, Ridker PM.

Ann Intern Med. 2006 Jul 4;145(1):21-9.

PMID:
16818925
10.

Association of LDL cholesterol and inflammation with cardiovascular events and mortality in hemodialysis patients with type 2 diabetes mellitus.

Krane V, Winkler K, Drechsler C, Lilienthal J, März W, Wanner C; German Diabetes and Dialysis Study Investigators.

Am J Kidney Dis. 2009 Nov;54(5):902-11. doi: 10.1053/j.ajkd.2009.06.029. Epub 2009 Sep 25.

PMID:
19781835
11.

Relation of C-reactive protein levels to presence, extent, and severity of angiographic coronary artery disease.

Auer J, Rammer M, Berent R, Weber T, Lassnig E, Eber B.

Indian Heart J. 2002 May-Jun;54(3):284-8.

PMID:
12216925
12.

Inflammatory markers and the risk of coronary heart disease in men and women.

Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB.

N Engl J Med. 2004 Dec 16;351(25):2599-610.

13.

Intensive lipid lowering with atorvastatin in patients with stable coronary disease.

LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Fruchart JC, Gotto AM, Greten H, Kastelein JJ, Shepherd J, Wenger NK; Treating to New Targets (TNT) Investigators.

N Engl J Med. 2005 Apr 7;352(14):1425-35. Epub 2005 Mar 8.

14.

Comparison of relative and attributable risk of myocardial infarction and stroke according to C-reactive protein and low-density lipoprotein cholesterol levels.

Pischon T, Möhlig M, Hoffmann K, Spranger J, Weikert C, Willich SN, Pfeiffer AF, Boeing H.

Eur J Epidemiol. 2007;22(7):429-38. Epub 2007 Jun 8.

PMID:
17557140
15.

Ten-year mortality from cardiovascular disease in relation to cholesterol level among men with and without preexisting cardiovascular disease.

Pekkanen J, Linn S, Heiss G, Suchindran CM, Leon A, Rifkind BM, Tyroler HA.

N Engl J Med. 1990 Jun 14;322(24):1700-7.

16.

Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group.

Rubins HB, Robins SJ, Collins D, Fye CL, Anderson JW, Elam MB, Faas FH, Linares E, Schaefer EJ, Schectman G, Wilt TJ, Wittes J.

N Engl J Med. 1999 Aug 5;341(6):410-8.

17.

Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease.

Nissen SE, Tuzcu EM, Schoenhagen P, Crowe T, Sasiela WJ, Tsai J, Orazem J, Magorien RD, O'Shaughnessy C, Ganz P; Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) Investigators.

N Engl J Med. 2005 Jan 6;352(1):29-38.

18.

Reduction in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial.

Ridker PM, Danielson E, Fonseca FA, Genest J, Gotto AM Jr, Kastelein JJ, Koenig W, Libby P, Lorenzatti AJ, Macfadyen JG, Nordestgaard BG, Shepherd J, Willerson JT, Glynn RJ; JUPITER Trial Study Group.

Lancet. 2009 Apr 4;373(9670):1175-82. doi: 10.1016/S0140-6736(09)60447-5. Epub 2009 Mar 28.

PMID:
19329177
20.

Multiple biomarkers for the prediction of first major cardiovascular events and death.

Wang TJ, Gona P, Larson MG, Tofler GH, Levy D, Newton-Cheh C, Jacques PF, Rifai N, Selhub J, Robins SJ, Benjamin EJ, D'Agostino RB, Vasan RS.

N Engl J Med. 2006 Dec 21;355(25):2631-9.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk